Denovo Biopharma
10240 Science Center Drive
Suite 120
San Diego
California
United States
20 articles about Denovo Biopharma
-
Denovo Biopharma Announces a Major Breakthrough in Treatment-Resistant Depression with Precision Medicine
4/3/2024
Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker–guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).
-
Denovo Biopharma Creates Innovative Gene Registry Program to Support the First Precision Medicine for Treatment Resistant Depression
3/6/2023
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, set up a gene registry web portal and invites people who suffer from treatment-resistant depression (TRD) to visit www.iMatchDepression.com to help identify whether they or someone they know may be eligible to participate in a biomarker-guided global Phase 2b clinical trial (the "ENLIGHTEN" study).
-
First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) for Treatment-Resistant Depression
7/28/2022
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced dosing of the first patient in its biomarker-guided global Phase 2b clinical trial (the "ENLIGHTEN" study) to assess the safety and efficacy of DB104 (liafensine) in patients with treatment resistant depression (TRD).
-
Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine
12/16/2021
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced it discovered a novel genetic biomarker, Denovo Genomic Marker 7 (DGM7 TM), using its proprietary biomarker discovery platform.
-
Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome
12/14/2021
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced its partner Aytu BioPharma (Nasdaq: AYTU), has received FDA clearance for its IND application for enzastaurin and also Orphan Drug Designation (ODD) for enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).
-
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
12/9/2021
QIAGEN and Denovo Biopharma LLC announced a collaboration to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma, one of the most common lymphoid cancers.
-
Denovo Biopharma LLC's Phase 3 Pivotal ENGINE Study of DB102 (Enzastaurin) in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Is Fully Enrolled
11/12/2020
Denovo Biopharma, a pioneer in applying precision medicine to development of innovative therapies, today announced that its international Phase 3 registrational study for DB102 has fully enrolled
-
FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)
7/17/2020
Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DB102 (enzastaurin) being de
-
As Tocagen heads into its reverse merger with Forte Biosciences, Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.
-
Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets
4/28/2020
Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it is acquiring Tocagen's retroviral replicating vector platform (RRV) in its entirety, including its investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC (now known as DB107), and several early-stag
-
Denovo's new asset will target the Alpha2C adrenoceptor.
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more. -
Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance
2/21/2019
Denovo Biopharma announced the hiring of two senior executives, reporting to the CEO: Lei Zhang, MD, as Chief Medical Officer, Hematology, and Bruce M. Wagman, as Senior Vice President, Regulatory Affairs and Quality Assurance.
-
Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension
6/4/2018
Denovo Biopharma LLC announced it has entered into an exclusive global license agreement with the Stanford University School of Medicine that will enable Denovo to develop and commercialize its lead compound, enzastaurin (DB102).
-
Denovo Biopharma to Participate in Jefferies 2018 Global Healthcare Conference
5/31/2018
Denovo Biopharma LLC announced that Wen Luo, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Michael Haller, Ph.D., Chief Financial Officer, will be meeting with investors at the Jefferies 2018 Global Healthcare Conference.
-
The new 7600 square feet custom-built, state-of-the-art facility hosts Denovo's biomarker discovery platform, US clinical team and serves as Denovo's US headquarters.
-
Denovo Biopharma Receives FDA's Permission to Proceed a Phase III Clinical Trial with DB102 (Enzastaurin) in the First Line Treatment of High Risk DLBCL
10/24/2017
Denovo Biopharma announced today that the FDA has granted DB102 the IND clearance to proceed for a phase III trial to treat Diffuse Large B Cell Lymphoma in the US (ENGINE Study).
-
Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI
4/24/2017
-
Denovo Biopharma Acquires Global Rights To Depression Drug Candidate
4/24/2017
-
Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug
2/17/2017